Evidence map›Paper›PMID 20235831›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2010

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.

Lia L Lewis-Ximenez, Georg M Lauer, Julian Schulze Zur Wiesch, Paulo Sergio Fonseca de Sousa, Cleber F Ginuino, Gláucia Paranhos-Baccalá, Hanno Ulmer, Karl P Pfeiffer, Georg Goebel, João Luiz Pereira and 10 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Antibody Responses in Hepatitis C Infection.Cold Spring Harbor perspectives in medicine · 2021
    Review
  2. Article
  3. Article
  4. Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 5 countries.

Lia L Lewis-XimenezViral Hepatitis Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil. lialewis.fiocruz@gmail.com
Georg M Lauer
Julian Schulze Zur Wiesch
Paulo Sergio Fonseca de Sousa
Cleber F Ginuino
Gláucia Paranhos-Baccalá
Hanno Ulmer
Karl P Pfeiffer
Georg Goebel
João Luiz Pereira
Jaqueline Mendes de Oliveira
Clara Fumiko Tachibana Yoshida
Elisabeth Lampe
Carlos Eduardo Velloso
Marcelo Alves Pinto
Henrique Sergio Coelho
Adilson José Almeida
Carlos Augusto Fernandes
Arthur Y Kim
Alexander M Strasak
Hepatitis B Foundation · USInnsbruck Medical University · ATFundação Oswaldo Cruz · BRFondation Mérieux · FRHospital Geral de Bonsucesso · BRHospital Universitário Clementino Fraga Filho · BRMassachusetts General Hospital · USUniversity Medical Center Hamburg-Eppendorf · DE

Funding

The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
NIAID NIH HHS AI066345-05NIAID NIH HHS U19 AI066345
6 · The paper itself

Abstract

backgroundThe natural outcome of infection with hepatitis C virus (HCV) varies substantially among individuals. However, little is known about host and viral factors associated with a self-limiting or chronic evolution of HCV infection.

methodsFrom 1 January 2001 through 31 December 2008, a consecutive series of 65 patients from Rio de Janeiro, Brazil, with a well-documented diagnosis of acute HCV infection, acquired via various routes, were enrolled in this study. Patients were prospectively followed up for a median of 40 months after the estimated date of HCV infection with serial measurements of serum alanine aminotransferase, HCV RNA, and anti-HCV antibodies. Spontaneous viral clearance (SVC) was defined as undetectable levels of HCV RNA in serum, in the absence of treatment, for 3 consecutive HCV polymerase chain reaction tests within the first 6 months of follow-up. Cox proportional hazards regression was used to identify host and viral predictors of SVC.

resultsThe cumulative rate of SVC was 44.6% (95% confidence interval, 32.3%-57.5%). Compared with chronic HCV evolution, patients with self-limiting disease had significantly lower peak levels of anti-HCV antibodies (median, 109.0 vs 86.7 optical density-to-cutoff ratio [od/co]; P<.02), experienced disease symptoms more frequently (69.4% vs 100%; P<.001), and had lower viral load at first clinical presentation (median, 4.3 vs 0.0 log copies; P=.01). In multivariate analyses, low peak anti-HCV level (<93.5 od/co) was the only independent predictor for SVC; the hazard ratio compared with high anti-HCV levels (> or =93.5 od/co) was 2.62 (95% confidence interval, 1.11-6.19; P=.03).

conclusionOur data suggest that low levels of anti-HCV antibodies during the acute phase of HCV infection are independently related to spontaneous viral clearance.

Indexed as

AdultAgedAlanine TransaminaseBrazilFemaleFollow-Up StudiesHepatitis CHepatitis C AntibodiesHumansMaleMiddle AgedProspective StudiesRNA, ViralYoung AdultAlanine TransaminaseHepatitis C AntibodiesRNA, Viral

Identifiers

PMID20235831
PMCPMC3860186
OpenAlexW2157857553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.